# Astefania (NCT04873362)

> A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04873362
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: Atezolizumab; Trastuzumab Emtansine; Placebo; Trastuzumab
- Enrollment: 1188
- Primary outcome: Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS)

## Commentary we found

- Podcasts: 6
- YouTube: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=astefania-nct04873362

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04873362", "email": "<work email>"}; the inbox owner confirms by the emailed link.